Joining Qinecsa Solutions as Chair of the Board

I am delighted to share that I have been appointed Chair of the Board of Qinecsa Solutions, effective 1 July 2026. The company announced the appointment this week; you can read the official press release here.

Qinecsa is a global pharmacovigilance specialist. It combines scientific expertise with a flexible, technology-powered platform, and it is trusted by major life sciences organisations and health authorities around the world to help keep patients safe.

Why pharmacovigilance, and why now

Pharmacovigilance is one of those disciplines that most people never think about, and that everyone depends on. Every medicine on the market carries an obligation to monitor, understand and report its safety in the real world. The volume of safety information is growing, the regulatory expectations are rising, and the operational burden on life sciences companies is significant.

That is precisely the kind of environment in which technology, applied responsibly, can make a genuine difference. AI can materially improve how safety information is captured, reviewed, analysed and reported. It can take repetitive work away from experts so that scientific judgement is spent where it matters most. But in a safety-critical, regulated setting, human oversight and scientific rigour are not optional extras. They are the foundation on which any use of AI has to be built.

Qinecsa sits exactly at that intersection: deep domain expertise, an integrated technology and services offering, and a client base for whom trust is everything. The board’s job is to help the company scale that offering and apply AI responsibly across its products, service delivery and operations, with measurable outcomes for clients and, ultimately, better safety outcomes for patients.

The thread that connects the work

Readers of these notes will recognise the theme. Much of my writing here concerns what happens when deep technology, regulation and capital collide, and what boards owe the organisations they serve in those conditions. Pharmacovigilance is a concentrated version of that problem: scientific evidence, regulatory scrutiny, sensitive data, international operations and technology transformation, all at once.

I look forward to working with Qinecsa’s leadership team and my board colleagues, and to writing more on the governance of safety-critical AI as the work develops.